



(43) International Publication Date 24 October 2002 (24.10.2002)

PCT

(10) International Publication Number WO 02/082929 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/575, 31/716, A61P 3/06

A23L 1/30,

(74) Agent: BERGGREN OY AB; P. O. Box 16, FIN-00101 Helsinki (FI).

(21) International Application Number: PCT/FI02/00315

(22) International Filing Date: 12 April 2002 (12.04.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20010780

12 April 2001 (12.04.2001) FI

(71) Applicant (for all designated States except US): RAISIO BENECOL OY [FI/FI]; P. O. Box 101, FIN-21201 Raisio (FI).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WESTER, Ingmar [FI/FI]; Puolalanpuisto 1 A 2, FIN-20100 Turku (FI). PALMU, Tapio [FI/FI]; Koivukuja 6, FIN-21260 Raisio (FI). HOPIA, Anu [FI/FI]; Välitalontie 89A, FIN-00660 Helsinki (FI). ALHO-LEHTO, Pirjo [FI/FI]; Haimionkuja 4, FIN-21410 Vanhalinna (FI). VIRTANEN, Paula [FI/FI]; Säästäjänkatu 15 A 6, FIN-33840 Tampere (FI). POURU, Anniina [FI/FI]; Särkilahdenkatu 9 A 8, FIN-21200 Raisio (FI).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA. CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMPROVED EDIBLE COMPOSITIONS FOR LOWERING CHOLESTEROL

(57) Abstract: The present invention is related to improved compositions for reducing serum total and/or LDL cholesterol levels. The compositions are combinations of dietary fibre and plant sterol. The compositions are used as such or more advantageously in food products and comprise one or several fibres, preferably  $\beta$ -glucan, in combination with one or several plant sterols and/or stanols in their free and/or esterified forms.

10

15

20

1

# Improved edible compositions for lowering cholesterol

#### Field of Invention

The present invention relates to the field of nutrition. Especially it concerns improved compositions for oral use suitable for lowering blood serum cholesterol levels and methods for lowering the serum cholesterol levels.

## **Background of the Invention**

According to FAO and WHO dietary fibres are constituents of substances of both animal and plant origin that are resistant to hydrolysis by human alimentary enzymes. Another generally accepted definition is that dietary fibres are the remnants of edible plant cell polysaccharides, lignin and other associated substances resistant to digestion by the alimentary enzymes of humans. According to these two definitions fibres can be obtained from grains, legumes, fruits, vegetables, algae or other plants or microbial or animal origin either as extracts, concentrates, bran or specific part of plant material containing a sufficient amount of active fibre ingredient.

The dietary fibres consist of insoluble and soluble substances. The insoluble poly-saccharides include mainly cellulose and hemicellulose. The soluble poly-saccharides include  $\beta$ -glucans, plant extrudates (gums), mucilages, legume seed gums, seaweed polysaccharides, bacterial polysaccharides, resistant starch or non-polysaccharide lignins. The cholesterol lowering effects have mainly been associated to soluble fibres because of their viscosity behaviour but also insoluble fibres may affect the serum cholesterol levels.

β-glucan and especially β-glucan from oat is known to have cholesterol lowering effect, which has been acknowledged also by health authorities. FDA has approved a health claim on the cholesterol lowering effect for oat products containing at least 0.75 grams of oat β-glucan per serving. The amount of β-glucan needed for an effect on cholesterol levels is 3 grams per day (recommended daily dosage) divided to 3 or 4 servings per day.

FDA has also approved a healthy claim for soluble fibre of psyllium containing at least 1.7 grams of soluble fibre per serving and the recommended daily intake of soluble fibre is 7 grams.

25

30

Consumption of diets with high  $\beta$ -glucan content has shown to lower the total and low density lipoprotein (LDL) cholesterol level by 8-12% (Ripsin et al., J. Am. Med. Assoc. 1992 (267) 3317-3325, Braaten et al., Eur. J. Clin. Nutr. 1994 (48) 465-474)

- 5 There is also evidence of the cholesterol lowering effect of the soluble fibres of psyllium (Anderson et al., Am. J. Clin. Nutr. 2000 (71) 1433-8) inulin (Causey et al., Nutrition Research 2000, 20(2), 191-201) and rye (Leinonen et al., J. Nutr. 2000 (130) 164-170) as well as microbial β-glucans (Bell et al., Crit. Rew. in Food Sci. and Nutr. 1999, 39(2) 189-202).
- 10 It is known that plant sterols (i.e. sterols and stanols) as well as esters thereof have serum cholesterol level lowering effects. Stanol fatty acid esters and the cholesterol lowering effects thereof are disclosed in US Patent No. 5,502,045 and 6,174,560 as well as a suitable method for their preparation.
- Dietary intake of 2 to 3 g/day of plant sterols is reported to lower the serum LDL levels in man by on average 10%—14% thus reducing the risk of coronary heart disease (CHD). Plant sterols inhibit the absorption of biliary and dietary cholesterol from the intestinal lumen.

The current literature and especially FDA's conclusion to allow the health claim for plant sterols has increased the interest of the food industry in supplementing foods with plant sterols. Indeed, many such food items have recently been introduced into the market. It is assumed that new plant sterol containing foods will appear into the market rapidly.

This active launching of new plant sterol containing foods has raised a concern that a part of the population may have higher daily intake of plant sterols than needed to obtain an optimal cholesterol lowering effect. Short-term high intake of plant sterols has not been shown to be harmful. However, there are no data on possible long-term side effects of ingestion of high daily amounts of plant sterols. Furthermore, currently there is not a clear understanding on the biological impact of the increased serum level and thus higher systemic availability of plant sterols caused by increased intake from sterol-enriched foods, especially of foods enriched with unsaturated plant sterols (here called sterols). Therefore, there is a need of food products having a high enough reducing effect on total and/or LDL serum cholesterol levels and containing somewhat elevated levels of plant sterols, in which products the cholesterol reducing effect has still been enhanced by other means.

## **Summary of the Invention**

5

10

15

20

25

30

35

The present invention relates to improved compositions suitable for reducing serum total and/or LDL cholesterol levels in man. The compositions comprise combinations of dietary fibres and plant sterols. The compositions can be used as such or as pharmaceuticals or nutraceuticals or most advantageously in food products. The compositions comprise one or several fibres used in combination with one or several plant sterols (sterols and/or stanols) in their free and/or esterified forms. A typical example of such an improved composition is a mixture of plant sterols and a soluble fibre, such as oat  $\beta$ -glucan, advantageously used in foods. The food products contain at least two of the active ingredients in sufficient amounts to provide a reduction in serum total and/or LDL cholesterol levels. In a preferred embodiment of this invention such reduction in serum total and/or LDL cholesterol levels is obtained by oral ingestion of a low daily dose of plant sterols and a soluble fibre such as  $\beta$ -glucan. This can be provided for the consumer in an easy way by including both plant sterol and  $\beta$ -glucan in the same food product.

Since  $\beta$ -glucan increases the viscosity of the content of the intestine, it was expected that  $\beta$ -glucan would inhibit or substantially decrease the cholesterol-lowering effect of plant sterols. However, it was surprisingly found that the two active components work synergistically in reducing the blood serum total and/or LDL cholesterol levels. In the tests performed it was shown that plant sterols in combination with dietary fibre ( $\beta$ -glucan) had a reducing effect on the cholesterol levels that was greater than the possibly expected additive effect.

The present invention also discloses a method for minimising the daily intake of plant sterols in man still achieving a similar cholesterol lowering effect as obtained with recommended daily intake of plant sterols from commercial plant sterol enriched products. This is especially important as the daily amount of plant sterols needed for obtaining a reduction in serum total and LDL cholesterol can be reduced, thus preventing potential over-consumption of plant sterols. Furthermore, the commercial availability of plant sterols is limited. By the use of the compositions according to the present invention the plant sterols supply can be more effectively utilised with the aim of reducing the risk of coronary heart disease (CHD) in individuals and in the population. In addition commercial crude plant sterols are expensive due to their limited availability. The present invention provides a way of obtaining similar serum cholesterol reductions as obtained with plant sterols alone, but with a markedly lower daily intake of plant sterols. As dietary fibres are cheaper

than plant sterols-the present invention also provides a way of obtaining an optimal cholesterol lowering effect more cost effectively.

The present invention also provides a method to improve the sensory properties such as structure and mouthfeel of food products with high fibre content. Dietary fibre, especially soluble fibre is a food component with known and recognised cholesterol lowering effect. However, the cholesterol lowering effect is achieved with remarkably high fibre content, which very often cause organoleptic problems for foods deteriorating structure and mouthfeel of foods such as breads and cakes. The present invention combining dietary fibre and plant sterols in cholesterol lowering products such as foods provides a way to obtain nutritionally a cholesterol lowering effect by lower fibre content in foods. Furthermore, the daily amount needed of dietary fibres to obtain reductions in total and/or LDL cholesterol levels cause in many subjects gastrointestinal discomfort. The present invention provides means for reducing such gastrointestinal discomfort with at least as efficient cholesterol lowering effect.

In practising the present invention ingredients of special interest are plant sterol and  $\beta$ -glucan. Plant sterol and psyllium (the soluble fibres of psyllium) are another preferred combination as well as plant sterol and inulin or some other combination of above ingredients such as  $\beta$ -glucan, inulin and plant sterol.

# 20 Detailed Description of the Invention

5

10

15

25

30

In one aspect of the present invention there is provided a food product for lowering serum total and/or LDL cholesterol levels comprising at least one basic nutritional ingredient, dietary fibre and a plant sterol, said dietary fibre and said plant sterol both being present in a higher amount than the one naturally occurring in the basic nutritional ingredient(s).

Dietary fibre is in this specification meant to include all edible fibres that have a lowering effect on the serum total and/or LDL cholesterol levels. Said dietary fibre is preferably a soluble fibre, such as  $\beta$ -glucan. By  $\beta$ -glucan is here meant intact  $\beta$ -glucans. An especially preferred dietary fibre is oat  $\beta$ -glucan. By soluble fibre is here meant soluble fibres that lower the serum total and/or LDL cholesterol levels. Other suitable fibres than  $\beta$ -glucan are inulin, the soluble fibres of psyllium (preferably used together with the insoluble fibres of psyllium), glucomannans, galactomannans, gum arabicum and guar gum. The term inulin is here meant to include all fructo oligosaccharides that can be measured by the AOAC standard

10

15

20

30

method 997.08. Use of mixtures of any of these fibres, such as e.g. inulin and  $\beta$ -glucan is also preferred.

By the term plant sterol is in this specification meant both sterols and saturated sterols i.e. stanols either in their free form or esterified with e.g. fatty acids (2—24 carbon atoms, saturated, monounsaturated or polyunsaturated, including also special fatty acids such as conjugated fatty acids (e.g. CLA) and EPA and DHA), hydroxybenzoic acids or hydroxycinnamic acids (ferrulic or coumaric acids) or other organic acids such as e.g. di- or tricarboxylic acids and/or hydroxy acids.

In this specification the sterols include 4-desmethyl sterols, 4-monomethyl sterols, and 4,4-dimethyl sterols (triterpene alcohols) and the stanols include 4-desmetyl stanols, 4-monomethyl stanols and 4,4-dimethyl stanols. Typical 4-desmethyl sterols are sitosterol, campesterol, stigmasterol, brassicasterol, 22-dehydro-brassicasterol,  $\Delta 5$ -avenasterol. Typical 4,4-dimethyl sterols are cycloartenol, 24-metylenecycloartanol and cyclobranol. Typical stanols are sitostanol, campestanol and their 24-epimers, cycloartanol and saturated forms obtainable e.g. by saturation of triterpene alcohols (cycloartenol, 24-metylenecycloartanol and cyclobranol).

By the term plant sterol is in this specification further meant all possible natural blends of 4-desmethyl sterols and stanols, 4-monomethyl sterols and stanols, 4,4-dimethyl sterols and stanols and mixtures of natural blends as well as any individual 4-desmethyl sterol, 4-monomethyl sterol or 4,4-dimethyl sterol or their corresponding saturated forms.

The amounts of plant sterol are in this specification calculated as plant sterol equivalents i.e. as the amount of free plant sterol.

Preferably the plant sterol is esterified and most preferably it is a plant sterol fatty acid ester. The fatty acid ester is technically very suitable to incorporate in a wide range of different products and it is especially preferred as it produces a fibre-rich food product with good organoleptic properties.

Preferably the plant sterol is a stanol because its absorption is neglectable and the use of stanol is therefore safer. Also the cholesterol lowering effect seems to be stronger with stanols.

The food product of the present invention can be in the form of various food compositions, including

- fresh bakery products (fresh bread, cakes, muffins, waffles etc.),

15

25

30

- dry bakery products (crispbread, biscuits, crackers etc.),
- cereal products (breakfast cereals, fibre and sterol enriched flours, mueslis, cereal based and muesli bars, such bars possibly containing chocolate, pasta products, snacks etc.),
- 5 bran products (granulated and/or toasted bran products, flavoured and/or sterol coated bran products and bran-bran mixes etc.),
  - beverages (alcoholic or non-alcoholic drinks, juices and juice-type mixed drinks, and dietary supplement and meal replacement drinks etc. as well as concentrates or premixes for beverages (whereby the plant sterol and  $\beta$ -glucan content is calculated for the ready to use -form),
  - dairy (milk based products, like milkshake, yoghurt, ice cream, desserts, cheese, spreads etc.) and/or non-dairy products (milk-type cereal and/or vegetable products and fermented cereal and/or vegetable products such as drinkables, desserts, yoghurt-, ice cream-, cheese-type products etc.). An especially preferred food product is a cereal milk product, preferably oat milk product or a product based on that, such as ice cream,
  - ready mixes (for baking e.g. breads, cakes, muffins, waffles, pizzas, pancakes; or for cooking e.g. soups, sauces, desserts, puddings) to be used in preparing or manufacturing of foods
- meat products (sausages, meat-balls, cold cuts etc.)
  - vegetable oil based products (spreads, salad oils, mayonnaise etc.)

In a second aspect of the present invention there is provided a pharmaceutical or nutraceutical composition for lowering serum total and/or LDL cholesterol levels comprising at least one compounding agent, a dietary fibre and a plant sterol, the weight ratio of said plant sterol to said dietary fibre being 1 to 2—5. The compounding agent can be any pharmaceutically acceptable diluent or excipient or coating agent. The composition can be in any suitable form e.g. tablets, granules, powder, capsules or dispersions.

The present invention also relates to the use of a composition comprising dietary fibre and a plant sterol in a combined amount effective for lowering serum total and/or LDL cholesterol levels for preparing a medicament for oral administration for lowering serum total and/or LDL cholesterol levels.

The products and compositions of the present invention contain at least two active ingredients in sufficient amounts to provide a reduction in serum total and/or LDL cholesterol levels. The daily intake of the compositions as such or when used in foods is such that it supplies a daily intake of plant sterols (calculated as sterol

equivalents) of 0.4—5 g, preferably 0.5—2.5 g, more preferably 0.8—2 g and most preferably 0.8—1.6 g and a daily intake of soluble fibre of 1—10 g, preferably 2—5 g and more preferably 2—3 g.

In a further aspect of the invention there is provided a method for lowering serum total and/or LDL cholesterol levels of a subject, comprising orally administering to the subject a composition comprising dietary fibre and a plant sterol in a combined amount effective for lowering serum total and/or LDL cholesterol levels.

A preferred embodiment of the present invention provides a way of obtaining reductions in serum total and/or LDL cholesterol levels with a combined use of elevated but low daily doses of plant sterols and  $\beta$ -glucan.

The present invention also makes it possible to reduce the daily intake of plant sterols in man still achieving similar cholesterol lowering effects as obtained with generally recommended daily intake of plant sterols (1.6—3 g) which can be achieved e.g. by consuming plant sterol-enriched commercial products.

According to the present invention it is also possible to lower the fibre content of food products with enhanced fibre content especially purposed for cholesterol lowering, thus improving e.g. the technological properties of such foods, their structure and organoleptic properties.

Further, the present invention provides a method to reduce or prevent the development of atherosclerosis in humans by dietary means including plant sterol and dietary fibre.

In a preferred embodiment of this invention the reduction in serum total and LDL cholesterol is obtained by oral ingestion of a low daily dose of plant sterols and a soluble fibre such as  $\beta$ -glucan and/or the soluble fibres of psyllium.

In another preferred embodiment of this invention the reduction in serum total and LDL cholesterol is obtained by oral ingestion of a low daily dose of plant sterols and a soluble fibre such as β-glucan and/or inulin.

The present invention is especially directed to an optimal daily intake of plant sterol and soluble fibre to achieve a nutritionally significant serum total and/or LDL cholesterol lowering effect in form of a food product as part of the daily diet.

When  $\beta$ -glucan is combined with plant sterols the optimal daily intake of plant sterol is less than 1.5 g/day (calculated as sterol equivalents), more preferably about

30

-1 g plant sterol/day in combination with 2—5 g, more preferably about 2.5 g soluble fibre preferably β-glucan /day. The invention is also directed to a food or drink containing at least 10% of the optimal daily intake/portion of the compositions.

It was surprisingly also realised that the weight ratio of plant sterol (calculated as sterol equivalents) to β-glucan at a range of 1 to 2—5 (i.e. 0.2—0.5) gave unexpected good synergistic effects. Also from a technical point of view this ratio seems to be surprisingly suitable for manufacturing a wide range of food products. The structure also seems to be soft and the food product tasty i.e. the organoleptic properties are improved in many foods where the ratio is in the mentioned range.

- 10 According to the present invention the dietary fibre can be incorporated into the food products or compositions as fibre concentrate or as flour or fibre containing sufficient amount of active ingredient. Mostly preferred are β-glucan enriched flour fractions like fibre-rich oat bran, enriched oat flake, enriched oat flour or any kind of β-glucan concentrates, extracts or other isolates.
- The main advantages of the present invention obtained by combining the intake of active ingredients into a food product containing a sufficient amount of  $\beta$ -glucan and plant sterols are:
  - synergistic total and/or LDL cholesterol lowering effect of  $\beta$ -glucan and plant sterols
- 20 enhanced serum cholesterol lowering effect compared to plant sterols alone
  - lower daily intake of plant sterols is needed compared to plant sterols alone to achieve the same cholesterol reducing effect
  - lower fibre content of high fibre foods for improved technological properties, structure and organoleptic properties
- 25 lowering the risk for coronary heart disease.

The two active ingredients of the present invention are incorporated into the daily diet in the form of food products containing a sufficient amount of the ingredients. The content of the two ingredients in food products is typically from 0.05 to 12.5 g of plant sterols, preferably from 0.05 to 2 g, and from 0.1 to 25 g of soluble fibre, preferably from 0.1 to 5 g in 100 g food product.

In the following some typical food products of the present invention and the preferred amounts of the  $\beta$ -glucan and plant sterol included therein are set forth. The percentages are calculated on the basis of the weight of the food product.

Beverage comprising  $\beta$ -glucan in an amount of 0.1—5%, preferably 0.5—1%, and plant sterol in an amount of 0.05—4%, preferably 0.2—1.5%.

Fresh bakery product comprising  $\beta$ -glucan in an amount of 0.9—16%, preferably 2.4—10%, and more preferably 3—5%, and plant sterol in an amount of 0.3—8%, preferably 0.8—5%, and more preferably 1—4%.

Dry bakery product comprising  $\beta$ -glucan in an amount of 1.0—20%, preferably 3.2—15% and more preferably 4.4—10%, and plant sterol in an amount of 0.5—10%, preferably 1.6—7.5% and more preferably 2.2—5%.

Cereal product comprising β-glucan in an amount of 0.8—20%, preferably 1.6—10 %, more preferably 2-10%, and plant sterol in an amount of 0.4—10%, preferably 0.8—8%, more preferably 1-5%.

Bran product comprising  $\beta$ -glucan in an amount of 4%—25%, preferably 6—20%, and plant sterol in an amount of 0.8—12.5%, preferably 1.2—10%.

Dairy or non-dairy product (e.g. fermentated cereal product) comprising β-glucan in an amount of 0.1—20%, preferably 0.8—8%, more preferably 0.8—5%, and plant sterol in an amount of 0.05—10%, preferably 0.4—4%, more preferably 0.4—2.5%.

Vegetable oil based product comprising  $\beta$ -glucan in an amount of 0.6—16%, preferably 2.6—10%, more preferably 2.6—5%, and plant sterol in an amount of 0.2—8%, preferably 1.3—5%, more preferably 1.3—2.5%.

Meat product comprising β-glucan in an amount of 0.1—16%, preferably 0.2—5%, and plant sterol in an amount of 0.05—8%, preferably 0.1—2.5%.

Ready mix comprising  $\beta$ -glucan in an amount of 0.1—20%, preferably 1—10%, and plant sterol in an amount of 0.05—10%, preferably 0.5—5%.

For plant sterols the intake is preferably from 0.4 to 5 g/day, more preferably from 0.5 to 2.5 g/day and most preferably about 1 g plant sterol/day divided into 0.5—5 servings as free or in esterified form. For soluble fibre the intake is preferably from 1 to 10 g/day, more preferably from 2 to 5 g/day and most preferably about 2.5 g soluble fibre/day in 1—5 servings of food items. In food items the level of active

ingredient is preferably 50% of the daily need/serving (from 10% to 200% per serving).

The combination of the two active ingredients (soluble fibre, especially  $\beta$ -glucan, and plant sterol) provides enhanced cholesterol lowering effect as compared to the two active ingredients alone.

According to one preferred embodiment food products according to the invention contain in addition to plant sterol and  $\beta$ -glucan also inulin. Typically these food products contain from 0.05 to 12.5 g of plant sterols, preferably from 0.05 to 2 g, and from 0.1 to 25 g of soluble fibre, preferably from 0.3 to 15 g in 100 g food product, wherein the soluble fibre comprises from 0.05 to 24.95 g of  $\beta$ -glucan, preferably from 0.1 to 5 g, and from 0.05 to 24.95 g of inulin, preferably from 0.2 to 10 g in 100 g food product.

In food products with high water content (e.g. more than 30%, preferably more than 50%, even more preferably more than 75%) (e.g. beverages, desserts, dairy and non-dairy food products) a high amount of  $\beta$ -glucan is not very desirable because of the high viscosity obtained when using most of the currently existing commercial  $\beta$ -glucan rich concentrates. It was noticed that by adding inulin in addition to  $\beta$ -glucan and plant sterol very attractive food products could be prepared also outside the preferred plant sterol to  $\beta$ -glucan weight ratio (1 to 2—5). Without any adverse effect on the synergistic cholesterol lowering features the amount of  $\beta$ -glucan could be reduced e.g. by adding at least the same amount of inulin to the food product. Typically the amount of inulin to soluble fibre ( $\beta$ -glucan and inulin) is 0.3—0.95:1, more preferably 0.6—0.9:1 in these products.

25

30

10

15

20

The advantages of adding a sufficient amount of inulin or replacing a part of the  $\beta$ -glucan with inulin in a product that contains  $\beta$ -glucan and plant sterols compared to a product that contains only plant sterols and  $\beta$ -glucan are e.g.

- enhanced serum cholesterol lowering effect compared to plant sterols and  $\beta$ glucan alone
- enhanced prebiotic properties
- improvement of the technological structure of certain products such as ice cream, pasta products, bakery products and desserts
- improvement of the sensory properties of certain products such as ice cream, pasta products, bakery products, desserts, beverages and drinkables.

25

35

In the following some typical food products of the present invention and the preferred amounts of  $\beta$ -glucan, inulin and plant sterol included therein are set forth. The percentages are calculated on the basis of the weight of the food product.

5 Beverage comprising β-glucan in an amount of 0.1—2%, preferably 0.3—1%, inulin in an amount of 0.2—10%, preferably 0.5—8%, and plant sterol in an amount of 0.05—4%, preferably 0.2—1.5%.

Dairy and/or non-dairy product (e.g. fermentated cereal product) comprising β-glucan in an amount of 0.1—5%, preferably 0.5—3%, more preferably 0.8—2.5%, inulin in an amount of 0.1-15%, preferably 0.2-10% and more preferably 0.5—6%, and plant sterol in an amount of 0.05—10%, preferably 0.4—4%, more preferably 0.4—2.5%.

Fresh bakery product comprising β-glucan in an amount of 0.9—16%, preferably 2.4—10%, and more preferably 3—5%, inulin in an amount of 0.5—10 %, preferably 1—6% and more preferably 1—3%, and plant sterol in an amount of 0.3—8%, preferably 0.8—5%, and more preferably 1—4%.

An especially preferred embodiment is an oat milk product or oat milk based product, such as oat milk based ice cream. These type of food product may typically comprise  $\beta$ -glucan in an amount of 0.1—5%, preferably 0.2—3.5% and more preferably 0.5—2.5%, inulin in an amount of 0.5—10%, preferably 1—6% and more preferably 1—3%, and plant sterol in an amount of 0.05—8%, preferably 0.5—5% and more preferably 0.8—2%. A preferred combination of the active ingredients in these type of food products comprises 1—2,5%  $\beta$ -glucan, 0.5—10% inulin and 0.1-5% plant sterol. Besides all other in this specification already mentioned beneficial features, the taste of an oat milk product comprising the three active ingredients is surprisingly excellent and brings forward a soft taste of oat by weakening the strong taste effect of  $\beta$ -glucan.

The oat milk product may naturally contain some amounts of β-glucan, e.g. 0.1—30 0.5%. Also these natural β-glucan containing oat, milk products are meant to be included in this preferred embodiment of the present invention.

The improved efficacy of a food product containing a combination of oat  $\beta$ -glucan and plant sterols was shown in a controlled study. Plant sterols were incorporated into the diet by providing 0.5 g stanol (administered as fatty acid ester) in a food item twice a day. Oat fibre containing 1.25 g  $\beta$ -glucan was incorporated into a food

item consumed twice a day. A food product-according to the invention containing both 0.5 g stanol (administered as fatty acid ester) and 1.25 g  $\beta$ -glucan was consumed twice a day by a third group of subjects.

The serum total and LDL cholesterol lowering effect of the food product containing the composition according to the invention was markedly higher than that of foods containing either of the active components alone and even higher than the possibly expected additive effect. Thus, it was concluded that plant sterol esters and  $\beta$ -glucan have a synergistic effect in lowering serum total and LDL cholesterol.

When incorporated into the diet the combined effect of  $\beta$ -glucan and plant sterols is beneficial as follows:

- to achieve enhanced cholesterol lowering effect of plant sterols when incorporated simultaneously into the diet with oat  $\beta$ -glucan. The combination of plant sterols and oat  $\beta$ -glucan is most preferably incorporated into foods designed for part of healthy diet.
- to decrease the dietary intake of plant sterols when combined and incorporated simultaneously with oat β-glucan into the daily diet with special aim to lower serum total and LDL cholesterol.
  - to lower the risk of CHD by means of lowering serum cholesterol levels.

It is evident from prior art that plant sterols, especially stanol fatty acid esters more 20 effectively reduce serum total and LDL cholesterol as compared to dietary fibres such as β-glucan. The cholesterol-lowering effect of β-glucan is not as strong especially when used as part of recommended diets. It was, however, surprisingly found that a low daily dose of β-glucan in combination with stanol ester had a synergistic cholesterol lowering effect. Surprisingly similar reduction as seen with 25 optimal daily intake of stanol ester alone was obtained. Thus, advantageously the daily intake of plant sterols can be decreased by combining the beneficial effect of plant sterols and other cholesterol lowering dietary components to achieve similar cholesterol lowering effect as obtained with optimal daily intake (2 -3 g/day) of plant sterols. This approach advantageously reduces the daily intake of plant sterols, 30 leading to a more balanced use of plant sterols. The synergistic effect is especially profound at daily intakes of at most 2 g plant sterol.

An especially preferred embodiment of the invention is the daily oral use of 0.8—1.6 g plant sterols (calculated as sterol equivalent), preferably 0.8—1.2 g plant

sterol in combination with at least 1.6 g  $\beta$ -glucan, preferably 2—5 g, and most preferably 2—3g  $\beta$ -glucan. Preferably the plant sterol used is a plant sterol fatty acid ester and even more preferred it is a plant sterol fatty acid ester containing a substantial amount of stanol fatty acid ester e.g. at least 30% stanol fatty acid ester.

In the following the invention will be further illustrated by means of examples. In this specification the percentages are % by weight unless otherwise specified.

## Example 1

A muffin or cake containing oat fibre (containing  $\beta$ -glucan) and sterol ester in effective amounts

10	Ingredie	ents	Dietary fibre (g)	β-glucan (g)
	223 g	wheat flour	6.7	
	255 g	fibre enriched oat bran	55	30
	380 g	sugar		
	370 g	vegetable fat		
15	25 g	sterol fatty acid ester		
		(15 g sterol equivalents)		
	92 g	egg powder		
	24 g	whey powder		
	16 g	baking powder		
20	8.5 g	lecithin		
	1.5 g	salt and flavorings		
	370 g	water		

The cake and the muffins were prepared in a conventional way.

The plant sterol content was 0.94% and the  $\beta$ -glucan content 1.89% of the ready product. The weight ratio of plant sterol to  $\beta$ -glucan was 0.50.

# Example 2

30

Oat fibre and plant sterol are combined in an oat milk drink or dessert with efficient amount of both active ingredients. Some drinks and desserts are prepared by adding inulin and possibly reducing the amount of  $\beta$ -glucan to obtain suitable products with synergistic cholesterol lowering effect.

Ingredients: Water, soluble fibre enriched oat concentrate, vegetable oil, plant sterolfatty acid ester, emulsifier, stabilising agent, and possibly inulin. The following compositions were made:

		1	2	3	4	5
5		drink	dessert	dessert		dessert
	Plant sterol content	0.25	0.8	1.2	1.6	1.2 g/100 g
	β-glucan content	0.50	2.3	2.5	3.6	2.0 g/100 g
	inulin content	0 .	0	0 .	0	4.0 g/100 g
	sterol: (β-glucan + inulin)	0.50	0.35	0.48	0.44	0.20
10	inulin : (β-glucan + inulin)	•				0.67
		6	7	8	9	10
		drink	drink	drink	drink	drink
	Plant sterol content	0.25	0.8	1.2	1.6	1.0 g/100 g
15	β-glucan content	0.50	0.5	0.5	0.5	0.5 g/100 g
	inulin content	0.50	1.8	2.0	3.1	4.5 g/100 g
•	sterol: (β-glucan + inulin)	0.25	0.35	0.48	0.44	0.20
	inulin: (β-glucan + inulin)	0.5	0.78	0.80	0.86	0.90

# 20 Example 3

Oat bran bread

	Ingredie	ents	Dietary fibre (g)	β-glucan (g)	
	570 g	fibre-rich oat bran	124.3	50.7	
	240 g	oat bran concentrate	105.6	52.8	
25	790 g	wheat flour	23.7		
	30 g	salt			
	50 g	stanol fatty acid ester			
	120 g	gluten			
	30 g	baking powder			
30	1750 g	water			

The stanol content of the ready bread was 0.96% and the  $\beta$ -glucan content was 3.3%. The weight ratio of plant sterol to  $\beta$ -glucan was 0.29.

Example 4

Fibre and plant sterol are combined in a bread pre-mix

	Ingredie	ents	Dietary fibre (g)	β-glucan (g)	
	455 g	oat flake	50	18.6	
5	450g	oat bran concentrate	140	104	
	250 g	malted rye flake	35	5	
	95 g	sourdough, dried	8		
	100 g	rye flour (whole grain)	14	2	
	95 g	stanol fatty acid ester			
10		(fatty acid composition as in rapese	ed oil)		

The pre-mix is then used for making bread by mixing the following ingredients with the pre-mix in a conventional manner:

Dietary fibre(g)

	3500 g	water	
15	1165 g	wheat flour	38
	60 g	salt	
	60 g	sugar	
	40 g	baking powder	
	75 g	sirup	

The ready bread contained 1.0% stanol and 2.3%  $\beta$ -glucan (the ratio of plant sterol to  $\beta$ -glucan was 0.43).

Example 5

Energy bar containing β-glucan and plant sterol

	Ingredie	ents	Dietary fibre (g)	β-glucan (g)
	200 g	oat flake	22	8
5	95 g	fibre-rich oat bran	19	9.5
	97 g	wheat flake	10	
	100 g	malted oat kernel	11	4
	140 g	sugar sirup		
	110 g	brown sugar		
10	40 g	concentrated apple juice	•	
	20 g	apple		
	60 g	raisin		
	105 g	vegetable fat		
	5 g	salt		
15	15 g	stanol fatty acid ester (9	g sterol equivalents)	
	10 g	flavourings		
	. 3 g	lecithin		

The bars contain 0.9% stanol and 2.2%  $\beta$ -glucan. The weight ratio between stanol and  $\beta$ -glucan is 0.42.

# 20 Example 6

Biscuit containing  $\beta$ -glucan and plant sterol

# Ingredients

	100 g	margarine containing stanol fatty a equivalents)	acid	ester	(8%	free	stanol	i.e.	sterol
25	170 g	sugar			ů.				
	90 g	fibre-rich oat bran containing	8 g	β-	gluca	n			
	40 g	oat bran concentrate containing	8.8 g	β-	gluca	n			
	2 g	baking powder							
	1 g	vanillin sugar							
30	120 g	egg							

The plant sterol content was 1.5% of the dough (1.8% per ready product), the  $\beta$ -glucan content 3.2% of the dough (3.9% per ready product) and the weight ratio of plant sterol to  $\beta$ -glucan was 0.46.

## Example 7

5 Muesli mixture containing β-glucan and stanol fatty acid ester

	Ingredie	ents	Dietary fibre (g)	β-glucan (g)
	430 g	oat flake	47	17.2
	95 g	fibre-rich oat bran	19	9
	50 g	rye flake	7	1
10	50 g	wheat germ	7	
	100 g	brown sugar		
	70 g	sugar syrup		
	5 g	salt	•	
	30 g	apple flake	3.5	
15	50 g	raisin	4.8	
	30 g	hazel nut	1.8	
	60 g	vegetable fat		
	20 g	stanol fatty acid ester		

stanol content 1.2% (as sterol equivalents)

20 β-glucan content 3.6%

Weight ratio of stanol to  $\beta$ -glucan 0.33

## Example 8

Fermented yoghurt-like cereal product containing β-glucan and plant sterol

# **Ingredients**

- 59.4 g water
  7 g fibre enriched oat bran (containing 0.7 g β-glucan)
  30 g berry jam (containing sugar, cowberry, blueberry, strawberry, raspberry, pectin, flavor)
  0.58 g plant sterol fatty acid ester
- 30 3 g lecithin

The mixture of water and oat bran was fermented using Lactobacillus and a bifidobacteria culture. The sterol was mixed with the lecithin and all ingredients were worked together.

The product contained plant sterol 0.35% and  $\beta$ -glucan 0.7%. The weight ratio between plant sterol and  $\beta$ -glucan was 0.5.

## Example 9

Fermented dairy product containing soluble fibre (inulin and  $\beta$ -glucan) and plant sterol

# **Ingredients**

10	31 g	milk
	31 g	oat milk
	45 g	fibre enriched oat bran (containing 3 g β-glucan)
	30 g	berry jam (containing sugar, cowberry, blueberry, strawberry, raspberry, pectin, flavor)
15	1.5 g	inulin
	1.6 g	sterol fatty acid ester (0.96 g sterol equivalents)
	10 g	lecithin
		bacteria culture (lactobacillus acidophilus, bifidobacterium etc.)

The sterol content of the product was 0.64%, the β-glucan content 2.0% and the soluble fibre (inulin and β-glucan) 3.0%. The weight ratio between sterol and β-glucan was 0.32 and between sterol and soluble fibre 0.21.

# Example 10

Fruit drink containing soluble fibre (\beta-glucan and inulin) and plant sterol

### **Ingredients**

	200 g	fruit juice concentrate (banana, pine apple, orange, grape, apricot, lemon,
5		passion fruit, guava, mango)
	5 g	fructose
	1 g	inulin
	10 g	fibre enriched oat bran (12% β-glucan)
	0.9 g	plant sterol fatty acid ester (= 0.54 g sterol equivalents)
10	5 g	lecithin
	2 g	β-glucan concentrate (25% β-glucan)
	1.5 g	calsium lactate
	775 g	water

The product contained 0.054% plant sterol and 0.17%  $\beta$ -glucan, and the soluble fibre content was 0.27%. The ratio of plant sterol to  $\beta$ -glucan was 1 : 3.1 (i.e. 0.32) and between plant sterol and soluble fibre ( $\beta$ -glucan and inulin) 1 : 5 (i.e. 0.2).

# Example 11

Vanilla ice-cream-type food product containing stanol ester, β-glucan and inulin

# **Ingredients**

20

	64.5 g	oat milk (containing 0.5 g β-glucan)
	8.0 g	sugar
25	6.5 g	vegetable oil
	6.0 g	inulin
	4.0 g	starch syrup
	1.7 g	plant stanol fatty acid ester (= 1 g plant stanol equivalents)
	6.0 g	β-glucan concentrate (25 % β-glucan)
30	3.0 g	emulgators (synthetic emulgators and lecithin)
	0.3 g	aromas (vanilin)

The product contained 1% plant stanol and 2%  $\beta$ -glucan, and the soluble fibre content was 8%. The ratio of plant sterol to  $\beta$ -glucan was 1 : 2 (i.e. 0.50) and

between plant sterol and soluble fibre ( $\beta$ -glucan and inulin) 1-: 8-(i.e. -0.125) and inulin to soluble fibre 1: 1.33 (i.e.0.75).

### Example 12

5

Fruit muesli containing stanol ester and  $\beta$ -glucan

# Ingredients

10	6 g	oat flake
	24 g	oat bran concentrate
	2.5 g	plant stanol ester (=1.5 g plant stanol equivalents)
	6.6 g	oat bran
	6.0 g	sugar
15	3.0 g	rice crispy
	3.5 g	vegetable oil
	4.5 g	syrup
	0.3 g	salt
	3.6 g	fruit mixture
20		

The product contained 2.5% plant stanol and 8.3 %  $\beta$ -glucan. The ratio of plant stanol to  $\beta$ -glucan was 1 : 3.3 (i.e. 0.30).

### Example 13

25 Fermented yoghurt-like cereal product containing β-glucan, inulin and plant sterol

### **Ingredients**

- 54 g water
  6 g fibre enriched oat bran (containing 0.6 g β-glucan)
  30 g berry jam (containing sugar, cowberry, blueberry, strawberry, raspberry, pectin, flavor)
  2 g plant sterol fatty acid ester
  - 5 g inulin
  - 3 g lecithin

WO 02/082929 PCT/FI02/00315

21

The mixture of water and oat bran was fermented using Lactobacillus and a bifidobacteria culture. The sterol was mixed with the lecithin and all ingredients were worked together.

The product contained plant sterol 1.2%, β-glucan 0.6% and inulin 5%. The weight ratio between plant sterol and soluble fibre (β-glucan and inulin) was 1:4.6 (i.e. 0.2) and the ratio of inulin to insoluble fibre (β-glucan and inulin) was 1:1.12 (i.e. 0.89).

#### Claims

- 1. A food product for lowering serum total and/or LDL cholesterol levels comprising at least one basic nutritional ingredient, dietary fibre and a plant sterol, said dietary fibre and said plant sterol both being present in a higher amount than the one naturally occurring in the basic nutritional ingredient(s).
- 2. The food product according to claim 1, wherein the dietary fibre comprises soluble fibre.
- 3. The food product according to claim 1 or 2, wherein the dietary fibre comprises  $\beta$ -glucan.
- 4. The food product according to any of claims 1 to 3, wherein the dietary fibre comprises oat β-glucan.
  - 5. The food product according to claim 1 or 2, wherein the dietary fibre comprises psyllium.
- 6. The food product according to claim 1 or 2, wherein the dietary fibre comprises inulin.
  - 7. The food product according to any of claims 1 to 6, wherein the plant sterol is selected from the group consisting of free sterols, free stanols, esterified sterols, esterified stanols and mixtures thereof.
- 8. The food product according to claim 7, wherein the esterified sterols comprise sterol fatty acid esters, and the esterified stanols comprise stanol fatty acid esters.
  - 9. The food product according to any of claims 1 to 8, wherein the dietary fibre and the plant sterol are present in a total amount being less than the amount of the individual dietary fibre or plant sterol required for obtaining the same reduction in serum total and/or LDL cholesterol levels.
- 25 10. The food product according to any of claims 3, 4 and 7 to 9, wherein the weight ratio of plant sterol (as sterol equivalents) to β-glucan is 1 to 2—5.
  - 11. The food product according to any of claims 1 to 10, wherein the amounts of the dietary fibre and plant sterol are such that the dietary fibre is consumed at a rate of 1 g to 10 g, preferably 2 g to 5 g per day and the plant sterol is consumed at a rate
- from 0.4 g to 5 g, preferably 0.8 g to 2 g per day.

- 12. The food product according to any of claims 1 to 11 comprising a beverage.
- 13. The food product according to claim 12, wherein the amount of  $\beta$ -glucan is 0.1—5%, preferably 0.5—1%, and the amount of the plant sterol is 0.05—4%, preferably 0.2—1.5% based on the weight of the food product.
- 5 14. The food product according to any of claims 1 to 11 comprising a fresh bakery product.
  - 15. The food product according to claim 14, wherein the amount of  $\beta$ -glucan is 0.9—16%, preferably 2.4—10% and more preferably 3—5%, and the amount of the plant sterol is 0.3—8%, preferably 0.8—5% and more preferably 1—4%, based on the weight of the food product.
  - 16. The food product according to any of claims 1 to 11 comprising a dry bakery product.
- 17. The food product according to claim 16, wherein the amount of β-glucan is 1.0—20%, preferably 3.2—15% and more preferably 4.4—10%, and the amount of the plant sterol is 0.5—10%, preferably 1.6—7.5% and more preferably 2.2—5%, based on the weight of the food product.
  - 18. The food product according to any of claims 1 to 11 comprising a cereal product.
- 19. The food product according to claim 18, wherein the amount of β-glucan is
   20 0.8—20%, preferably 1.6—16%, and the amount of the plant sterol is 0.4—10%, preferably 0.8—8% based on the weight of the food product.
  - 20. The food product according to any of claims 1 to 11 comprising a bran product.
- 21. The food product according to claim 20, wherein the amount of β-glucan is
   25 4%—25%, preferably 6—20%, and the amount of the plant sterol is 0.8—12.5%, preferably 1.2—10% based on the weight of the food product.
  - 22. The food product according to any of claims 1 to 11 comprising a dairy and/or non-dairy, such as fermented cereal product.

- 23. The food product according to claim 22, wherein the amount of  $\beta$ -glucan is 0.1—20%, preferably 0.8—8%, and the amount of the plant sterol is 0.05—10%, preferably 0.4—4% based on the weight of the food product.
- 24. The food product according to any of claims 1 to 11 comprising a vegetable oil based product.
  - 25. The food product according to claim 24, wherein the amount of  $\beta$ -glucan is 0.6—16%, preferably 2.6—10%, and the amount of the plant sterol is 0.2—8%, preferably 1.3—5% based on the weight of the food product.
- 26. The food product according to any of claims 1 to 11 comprising a meat 10 product.
  - 27. The food product according to claim 26, wherein the amount of  $\beta$ -glucan is 0.1—16%, preferably 0.2—5%, and the amount of the plant sterol is 0.05—8%, preferably 0.1—2.5% based on the weight of the food product.
  - 28. The food product according to any of claims 1 to 11 comprising a ready mix.
- 15 29. The food product according to claim 28, wherein the amount of β-glucan is 0.1—20%, preferably 1—10%, and the amount of the plant sterol is 0.05—10%, preferably 0.5—5% based on the weight of the food product.
- 30. A pharmaceutical or nutraceutical composition for lowering serum total and/or LDL cholesterol levels comprising at least one compounding agent, dietary fibre
   20 and a plant sterol, the weight ratio of said plant sterol to said dietary fibre being 1 to 2—5.
  - 31. The pharmaceutical or nutraceutical composition according to claim 30 wherein the composition is a product as defined in any of claims 1 to 29.
- 32. Use of a composition comprising dietary fibre and a plant sterol in a combined amount effective for lowering serum total and/or LDL cholesterol levels for preparing a medicament for oral administration for lowering serum total and/or LDL cholesterol levels.
- 33. The use according to claim 32, wherein said combined amount is less than the amount of the individual dietary fibre or plant sterol required for obtaining the same reduction in serum total and/or LDL cholesterol levels.

- 34. The use according to claim 32 or 33, wherein the dietary fibre is administered at a rate of 1 g to 10 g, preferably 2 g to 5 g per day, and the plant sterol is administered at a rate of 0.4 g to 5 g, preferably 0.8 g to 2 g per day.
- 35. The use according to any of claims 32 to 34, wherein the composition is a product as defined in any of claims 1 to 31.
  - 36. A method for lowering serum total and/or LDL cholesterol levels of a subject, comprising orally administering to the subject a composition comprising dietary fibre and a plant sterol in a combined amount effective for lowering serum total and/or LDL cholesterol levels.
- 10 37. The method according to claim 36, wherein said combined amount is less than the amount of the individual dietary fibre or plant sterol required for obtaining the same reduction in serum total and/or LDL cholesterol levels.

- 38. The method according to claim 36 or 37, wherein the dietary fibre is administered at a rate of 1 g to 10 g, preferably 2 g to 5 g per day, and the plant sterol is administered at a rate of 0.4 g to 5 g, preferably 0.8 g to 2 g per day.
- 39. The method according to any of claims 36 to 38, wherein the composition is a product as defined in any of claims 1 to 31.

International Application No

PCT/FI 02/00315 A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A23L1/30 A611 A61K31/575 A61K31/716 A61P3/06 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 7 A23L A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) WPI Data, PAJ, BIOSIS, EPO-Internal C. DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. P,X WO 01 78534 A (PROCTER & GAMBLE) 1-4,7-39 25 October 2001 (2001-10-25) page 2, line 14 - line 30 page 7, line 6 - line 7 P,X WO 01 78522 A (PROCTER & GAMBLE) 1-5,7-39 25 October 2001 (2001-10-25) page 4, line 12 - line 24 page 17, line 28 page 20, line 5 - line 9 Further documents are listed in the continuation of box C. X Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not considered to be of particular relevance cited to understand the principle or theory underlying the "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or other means ments, such combination being obvious to a person skilled "P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 10 09. 2002 20 August 2002 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Terese Persson

International application No. PCT/FI 02/00315

# INTERNATIONAL SEARCH REPORT

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: 36–39 because they relate to subject matter not required to be searched by this Authority, namely:
	see FURTHER INFORMATION sheet PCT/ISA/210
2. X	Claims Nos.: 1, 30, 32, 36 (all partially) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Inte	rnational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Kemark	on Protest  The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of additional search fees.

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 36-39

Claims 36-39 relate to methods of treatment of the human or animal body by surgery or by therapy/ diagnostic methods practised on the human or animal body /Rule 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds/compositions.

Continuation of Box I.2

Claims Nos.: 1, 30, 32, 36 (all partially)

Present claims 1, 30, 32 and 36 relate to an extremely large number of possible food products and compositions, since the dietary fibre and plant sterol are not further specified. In fact, the claims contain so many options that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Consequently, the search has mainly been focused on those parts of the application which appear to be clear and concise, namely the dietary fibres mentioned on page 4, lines 26-33 in the present application and the plant sterols mentioned on page 5, lines 9-16 in the present application.

As a result, the rest of the claims relating to these food products and compositions will have the same limitation, i.e. they have mainly been searched with focus on the dietary fibres mentoned on page 4, lines 26-33 in the present application and the plant sterols mentioned on page 5, lines 9-16 in the present application.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

International Application No PCT/FI 02/00315

PC1/F1 02/00315
Relevant to claim No.
1,2,7-9, 11,12, 14,16, 18,20, 22,24, 26,28, 30-39
1-4,7-39
1-4,7-39
1-4,7-39
1,2,5, 7-9,11, 12,14, 16,18, 20,22, 24,26, 28,30-39

International Application No
PCT/FI 02/00315

	PCT/FI 02/00315
•	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
WO 99 11144 A (RICEX COMPANY INC ) 11 March 1999 (1999-03-11)	1,2,7-9, 11,12, 14,16, 18,20, 22,24, 26,28, 30-39
page 4; tables 1,4-7	·
WO 00 30663 A (NUTRI PHARMA AS (NO)) 2 June 2000 (2000-06-02) page 1, line 5 - line 18 page 28, line 14 - line 33 page 35, line 4 - line 8	1-39
WO 99 55351 A (LEKO VLADIMIR) 4 November 1999 (1999-11-04)	1,2,6-9, 11,12, 14,16, 18,20, 22,24, 26,28, 30-39
page 6, line 3 - line 10 page 8, line 18 - line 19 page 13, line 3 - line 4	
WO 95 00158 A (BIO SPHERE TECHNOLOGY) 5 January 1995 (1995-01-05)	1,2,7-9, 11,12, 14,16, 18,20, 22,24, 26,28, 30-39
PATENT ABSTRACTS OF JAPAN vol. 012, no. 103 (C-485), 5 April 1988 (1988-04-05) & JP 62 234027 A (ASAHI CHEM IND CO LTD), 14 October 1987 (1987-10-14) abstract	1-4,7-39
US 5 502 045 A (WESTER INGMAR ET AL) 26 March 1996 (1996-03-26) the whole document	8
EP 0 986 962 A (MCNEIL PPC INC) 22 March 2000 (2000-03-22) page 3, line 20 - line 24 abstract	1-39
	page 4; tables 1,4-7  W0 00 30663 A (NUTRI PHARMA AS (NO)) 2 June 2000 (2000-06-02) page 1, line 5 - line 18 page 28, line 14 - line 33 page 35, line 4 - line 8  W0 99 55351 A (LEKO VLADIMIR) 4 November 1999 (1999-11-04)  page 8, line 18 - line 19 page 13, line 3 - line 4  W0 95 00158 A (BIO SPHERE TECHNOLOGY) 5 January 1995 (1995-01-05)  page 3  PATENT ABSTRACTS OF JAPAN vol. 012, no. 103 (C-485), 5 April 1988 (1988-04-05) & JP 62 234027 A (ASAHI CHEM IND CO LTD), 14 October 1987 (1987-10-14) abstract  US 5 502 045 A (WESTER INGMAR ET AL) 26 March 1996 (1996-03-26) the whole document  EP 0 986 962 A (MCNEIL PPC INC) 22 March 2000 (2000-03-22)

International Application No

-		PCT/FI 02/00315	
	ntion) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.
•	BRAATEN J T ET AL: "OAT BETA-GLUCAN REDUCES BLOOD CHOLESTEROL CONCENTRATION IN HYPERCHOLESTEROLEMIC SUBJECTS" EUROPEAN JOURNAL OF CLINICAL NUTRITION, XX, XX, vol. 48, July 1994 (1994-07), pages 465-474, XP001027909 the whole document		1-39
į			
	•		
		ļ	
	•		
		j	
	·		
ŀ			·
į		.	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

Information on patent family members

International Application No PCT/FI 02/00315

				02/00313
Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 0178534 A	25-10-2001	AU WO US	5339201 A 0178534 A2 2002012733 A1	30-10-2001 25-10-2001 31-01-2002
WO 0178522 A	25-10-2001	AU WO US US	5342001 A 0178522 A2 2002012722 A1 2002015761 A1 2002094359 A1	30-10-2001 25-10-2001 31-01-2002 07-02-2002 18-07-2002
WO 0154686 A	02-08-2001	AU WO	3454801 A 0154686 A2	07-08-2001 02-08-2001
WO 0178529 A	25-10-2001	AU WO US	5329401 A 0178529 A2 2002018807 A1	30-10-2001 25-10-2001 14-02-2002
WO 0130359 A	03-05-2001	SE AU EP WO SE	517769 C2 1321101 A 1227816 A1 0130359 A1 9903915 A	16-07-2002 08-05-2001 07-08-2002 03-05-2001 30-04-2001
WO 9307167 A	15-04-1993	AT AU CA DE DE ES GR JP MX PT WO US CA MX	165367 T 2753292 A 2079544 A1 69225233 D1 69225233 T2 0607245 A1 2114948 T3 3026698 T3 6511250 T 9205703 A1 100922 A ,B 9307167 A1 5591836 A 2079543 A1 9205704 A1	15-05-1998 03-05-1993 05-04-1993 28-05-1998 19-11-1998 27-07-1994 16-06-1998 31-07-1998 15-12-1994 01-07-1993 29-10-1993 15-04-1993 07-01-1997 05-04-1993 01-07-1993
WO 9911144 A	11-03-1999	AU WO US US US	9209898 A 9911144 A1 6126943 A 6350473 B1 2002086069 A1	22-03-1999 11-03-1999 03-10-2000 26-02-2002 04-07-2002
WO 0030663 A	02-06-2000	AU BR EP WO	1511300 A 9915693 A 1143988 A1 0030663 A1	13-06-2000 14-08-2001 17-10-2001 02-06-2000
WO 9955351 A	04-11-1999	HR HR AU GB WO BR CN US	980109 A1 990080 A1 3622099 A 2363714 A 9955351 A1 9917211 A 1348380 T 2002102315 A1	31-08-2000 30-04-2001 16-11-1999 09-01-2002 04-11-1999 14-05-2002 08-05-2002 01-08-2002

Information on patent family members

International Application No PCT/FI 02/00315

					•	
Patent document cited in search report		Publication date		Patent family member(s)	Publication date	
WO 9500158	A	05-01-1995	AU WO US	7250694 A 9500158 A1 5747464 A	17-01-1995 05-01-1995 05-05-1998	
JP 62234027	Α	14-10-1987	NONE			İ
US 5502045	A	26-03-1996	WO AU CA DE DK EP FI HK HU JP NO PL RU US	9219640 A1 664827 B2 2102112 A1 69127207 D1 69127207 T2 594612 T3 0594612 A1 934869 A ,B, 964951 A 20011891 A 1001951 A1 65318 A2 6506909 T 933966 A 166991 B1 2095367 C1 6174560 B1 5958913 A	12-11-1992 07-12-1995 04-11-1992 11-09-1997 22-01-1998 01-09-1997 04-05-1994 03-11-1993 11-12-1996 26-09-2001 24-07-1998 02-05-1994 04-08-1994 04-08-1994 02-11-1993 31-07-1995 10-11-1997 16-01-2001 28-09-1999	
EP 0986962	A	22-03-2000	US AU BR EP JP NO US	6123978 A 4463699 A 9903979 A 0986962 A1 2000102361 A 994195 A 6399137 B1	26-09-2000 16-03-2000 05-09-2000 22-03-2000 11-04-2000 01-03-2000 04-06-2002	